CA2747235C - Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles - Google Patents

Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles Download PDF

Info

Publication number
CA2747235C
CA2747235C CA2747235A CA2747235A CA2747235C CA 2747235 C CA2747235 C CA 2747235C CA 2747235 A CA2747235 A CA 2747235A CA 2747235 A CA2747235 A CA 2747235A CA 2747235 C CA2747235 C CA 2747235C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
alkyl
formula
hydrogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2747235A
Other languages
English (en)
French (fr)
Other versions
CA2747235A1 (en
Inventor
Spyros Deftereos
Andreas Persidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovista Inc
Original Assignee
Biovista Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovista Inc filed Critical Biovista Inc
Publication of CA2747235A1 publication Critical patent/CA2747235A1/en
Application granted granted Critical
Publication of CA2747235C publication Critical patent/CA2747235C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2747235A 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles Active CA2747235C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12157408P 2008-12-11 2008-12-11
US61/121,574 2008-12-11
US23323509P 2009-08-12 2009-08-12
US61/233,235 2009-08-12
PCT/US2009/067673 WO2010068867A1 (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Publications (2)

Publication Number Publication Date
CA2747235A1 CA2747235A1 (en) 2010-06-17
CA2747235C true CA2747235C (en) 2021-02-09

Family

ID=42243090

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2747235A Active CA2747235C (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Country Status (9)

Country Link
US (1) US20110268699A1 (https=)
EP (1) EP2375900B1 (https=)
JP (1) JP2012512165A (https=)
CN (1) CN102395275A (https=)
AU (1) AU2009324495B2 (https=)
BR (1) BRPI0922871A2 (https=)
CA (1) CA2747235C (https=)
IL (1) IL213476A0 (https=)
WO (1) WO2010068867A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010031054A1 (en) 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
WO2013130422A1 (en) * 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
EA201591507A1 (ru) * 2013-02-15 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лахинимодом
KR101521807B1 (ko) * 2014-01-20 2015-05-20 한국전자통신연구원 데이터 전송 제어 장치 및 그 방법
HRP20241165T1 (hr) * 2014-05-09 2024-11-22 Tecnimede Sociedade Tecnico-Medicinal S.A. Mandelatne soli enantiomera pirlindola za upotrebu u medicini
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3520803A1 (en) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Novel uses
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
CA2617102A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
JP2010528016A (ja) * 2007-05-25 2010-08-19 メディベーション ニューロロジー， インコーポレイテッド 細胞を刺激するための方法および組成物

Also Published As

Publication number Publication date
EP2375900A4 (en) 2012-05-02
EP2375900A1 (en) 2011-10-19
EP2375900B1 (en) 2016-03-02
US20110268699A1 (en) 2011-11-03
AU2009324495B2 (en) 2015-12-24
WO2010068867A1 (en) 2010-06-17
AU2009324495A1 (en) 2011-07-28
BRPI0922871A2 (pt) 2016-11-16
CN102395275A (zh) 2012-03-28
IL213476A0 (en) 2011-07-31
CA2747235A1 (en) 2010-06-17
JP2012512165A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
CA2747235C (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
US20150111919A1 (en) Compositions and methods for treating multiple sclerosis
JP5490292B2 (ja) 医学的状態を治療するための方法、組成物、およびキット
JP2007332156A (ja) 性的不能の治療に有効な組合せ
US20070213388A1 (en) Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
JP2012502915A (ja) てんかんを治療する組成物及び方法
KR20180094965A (ko) 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
US20110237602A1 (en) Method for treating schizophrenia and related diseases
US20220362251A1 (en) Treatment of tachycardia
KR20200026925A (ko) 스타틴 조성물 및 시누클레인병변 치료에 사용하는 방법
JPWO2005094885A1 (ja) 慢性筋骨格痛を呈する疾患の予防および／または治療剤
US20210393595A1 (en) Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
JP4552189B2 (ja) 脊柱管狭窄症治療剤
US10172854B2 (en) Compositions and methods for treating mitochondrial diseases
JP2004508272A (ja) アセチルコリンエンハンサー
CN1247578C (zh) 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
HK1128593B (en) A composition suitable for ophthalmic administration
JP2018035086A (ja) 低活動膀胱の予防及び／又は治療薬
HK1032911A (en) Combination effective for the treatment of impotence
WO2001030388A1 (en) Tension-relieving agents for ciliary muscle

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260123

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260318